Jeff Fairman - Vaxcyte CoFounder Research
| PCVX Stock | USD 91.95 3.28 3.70% |
Insider
Jeff Fairman is CoFounder Research of Vaxcyte
| Age | 60 |
| Phone | 650 837 0111 |
| Web | https://vaxcyte.com |
Vaxcyte Management Efficiency
The company has return on total asset (ROA) of (0.1494) % which means that it has lost $0.1494 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2106) %, meaning that it created substantial loss on money invested by shareholders. Vaxcyte's management efficiency ratios could be used to measure how well Vaxcyte manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Francis Conway | Larimar Therapeutics | N/A | |
| William Kenan | Liquidia Technologies | N/A | |
| Prof MD | Ventyx Biosciences | N/A | |
| Noah MD | Travere Therapeutics | 57 | |
| Rob Henderson | Viridian Therapeutics | N/A | |
| Kim Kelderman | Bio Techne Corp | 58 | |
| MBA MBA | Biomarin Pharmaceutical | 71 | |
| Marvin Caruthers | Viridian Therapeutics | 85 | |
| CFA CFA | Travere Therapeutics | 40 | |
| Roger Jeffs | Liquidia Technologies | 63 | |
| Cedric MD | Apellis Pharmaceuticals | 53 | |
| Martin MD | Ventyx Biosciences | 49 | |
| Nancy Ruiz | Larimar Therapeutics | N/A | |
| CMO MBA | Viridian Therapeutics | 72 | |
| Alexander Nolte | Syndax Pharmaceuticals | 51 | |
| Michael MBA | Arcellx | N/A | |
| Philip Scalzo | Biomarin Pharmaceutical | N/A | |
| Sven MD | Merus BV | 62 | |
| Christopher MD | Nuvalent | 56 | |
| Vahe Bedian | Viridian Therapeutics | N/A | |
| Neeraj Teotia | Arcellx | 50 | |
Management Performance
| Return On Equity | -0.21 | ||||
| Return On Asset | -0.15 |
Vaxcyte Leadership Team
Elected by the shareholders, the Vaxcyte's board of directors comprises two types of representatives: Vaxcyte inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Vaxcyte. The board's role is to monitor Vaxcyte's management team and ensure that shareholders' interests are well served. Vaxcyte's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Vaxcyte's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Mikhail JD, General VP | ||
| Karen Alderete, Ex HR | ||
| Whitney Jones, Chief Officer | ||
| Andrew MBA, President CFO | ||
| Ashish MBA, CoFounder Officer | ||
| Jeff Fairman, CoFounder Research | ||
| Grant MBA, CEO CoFounder | ||
| Harp MBA, Senior Chain | ||
| MS MBA, Executive COO | ||
| Paul MBA, Senior Manufacturing | ||
| MBA MBA, Sr Manufacturing | ||
| Sam Iki, Senior Management | ||
| Janet Graesser, Senior Relations | ||
| Elvia Cowan, Senior Officer |
Vaxcyte Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Vaxcyte a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.21 | ||||
| Return On Asset | -0.15 | ||||
| Current Valuation | 9.31 B | ||||
| Shares Outstanding | 124.64 M | ||||
| Shares Owned By Insiders | 0.49 % | ||||
| Shares Owned By Institutions | 99.51 % | ||||
| Number Of Shares Shorted | 14.49 M | ||||
| Price To Book | 3.35 X | ||||
| Gross Profit | (75 M) | ||||
| EBITDA | (464.88 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Vaxcyte Stock Analysis
When running Vaxcyte's price analysis, check to measure Vaxcyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaxcyte is operating at the current time. Most of Vaxcyte's value examination focuses on studying past and present price action to predict the probability of Vaxcyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaxcyte's price. Additionally, you may evaluate how the addition of Vaxcyte to your portfolios can decrease your overall portfolio volatility.